Australia provisionally approves Covid vaccine for children aged 5-11 yrs

Australia's medical regulator, the Therapeutic Goods Administration (TGA), on Sunday provisionally approved Pfizer's coronavirus vaccine for children aged between 5 and 11.

vaccine
IANS Canberra
2 min read Last Updated : Dec 05 2021 | 1:59 PM IST

Australia's medical regulator, the Therapeutic Goods Administration (TGA), on Sunday provisionally approved Pfizer's coronavirus vaccine for children aged between 5 and 11.

Health Minister Greg Hunt said the federal government now expects the vaccine rollout for that cohort to start on January 10 pending approval from the Australian Technical Advisory Group on Immunisation (ATAGI).

"The vaccine dose approved by the TGA for children aged 5 to 11 is the same safe and effective vaccine used for other age cohorts, however is one-third the dose approved for those aged 12 and over," according to a media release from Hunt.

"As with other age groups, the use of this vaccine in children aged 5-11 years should be given in two doses at least 3 weeks apart."

There are approximately 2.3 million Australians in the 5-11 age bracket.

As of Saturday, about 88 per cent of Australians aged 16 and over and 67.5 per cent of 12-15 year-olds were fully vaccinated against Covid.

On Sunday, Australia reported more than 1,200 new locally-acquired coronavirus cases and eight deaths as the country continues to battle the third wave of the infection.

The majority of them -- 980 cases and seven deaths were in Victoria, the country's second-most populous state with Melbourne as the capital city.

The number of cases of the Omicron variant in Australia has increased to 18 after more cases were reported in the Australian Capital Territory (ACT) and New South Wales (NSW).

Parliament House in Canberra was closed on Sunday after a staffer to Greens leader Adam Bandt, tested positive for Covid.

--IANS

int/sks

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineAustralia

First Published: Dec 05 2021 | 1:59 PM IST

Next Story